

April 29, 2019

To Whom It May Concern:

Enclosed, please find Boehringer Ingelheim Pharmaceuticals, Inc. report submission in response to the requirements set forth by California SB 17. Pursuant to SB 17 and the implementing regulations, we limit the information included in this submission to that which is otherwise in the public domain or publicly available. Patent information provided is reflected in the public FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the "Orange Book").

Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Rd/P.O. Box 368
Ridgefield, CT 06877-0368
Telephone (203) 798-9988

If you have any questions, please do not hesitate to contact me.

Kind regards,

DocuSigned by:

Christine G. Marsh
Christine Marsh

2019.05.01 14:04:00